<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340896</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2014-03</org_study_id>
    <nct_id>NCT03340896</nct_id>
  </id_info>
  <brief_title>Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT</brief_title>
  <acronym>SALTORL</acronym>
  <official_title>Phase III Trial of Laryngeal Preservation Comparing Induction Chemotherapy With Cisplatin, 5-fluorouracil and Docetaxel (TPF) Followed by Radiotherapy and Concomitant Administration of Radiotherapy With Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compare the survival without laryngeal dysfunction 2 years after the end of&#xD;
      treatment, obtained by chemotherapy followed by radiotherapy or chemotherapy with cisplatin&#xD;
      administrated during radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with tumors classified as T3 or T4 larynx and hypopharynx, the usually&#xD;
      recommended treatment was total laryngectomy.This intervention allows to obtain locoregional&#xD;
      disease control in 75% of cases, without laryngectomy&#xD;
&#xD;
      TPF arm followed by radiotherapy was validated in a Phase III (GORTEC 2000-01), it will be&#xD;
      the standard treatment.&#xD;
&#xD;
      The RTOG study concluded that chemotherapy administrated during radiotherapy became a&#xD;
      standard of laryngeal preservation.&#xD;
&#xD;
      Taking together all these considerations, it is necessary to perform a direct comparison in a&#xD;
      randomized trial to further test this hypothesis. Chemotherapy followed by radiotherapy will&#xD;
      be the standard arm. It hopes to increase the survival rate from 52% to 65% in the&#xD;
      experimental arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2015</start_date>
  <completion_date type="Anticipated">September 24, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 24, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>free survival</measure>
    <time_frame>24 months after treatment initiation</time_frame>
    <description>Minimum time between randomization and the occurrence of events such as: death, total laryngectomy, tracheotomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
    <description>&quot;From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>60 months</time_frame>
    <description>&quot;From date of randomization until the date of first documented progression assessed up to 60 months&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Larynx Preservation</measure>
    <time_frame>24 months after treatment initiation</time_frame>
    <description>From date of randomization up to 24 months evaluated by dynamic deglutition videoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of salvage surgery</measure>
    <time_frame>60 months after randomization</time_frame>
    <description>Assessing the number of recurrences that could be successfully treated with salvage surgery and description of postoperative</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>TPF followed by radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction chemotherapy by Docetaxel 75 mg/m² day 1,cisplatin 75 mg/m² day 1 and 5 fluorouracil 750mg/m²(day 1 to day 5) 3 cycles day1, day 22, day 43 followed (for responders or stable disease patients) by radiotherapy&#xD;
Radiotherapy ;70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug and radiation • Cisplatin: 100 mg / m² administered IV at J1, J22 and J43 of radiotherapy&#xD;
. Radiotherapy 70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)</description>
    <arm_group_label>TPF followed by radiotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.</description>
    <arm_group_label>Cisplatin and radiotherapy</arm_group_label>
    <arm_group_label>TPF followed by radiotherapy</arm_group_label>
    <other_name>Cisplatine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)</description>
    <arm_group_label>TPF followed by radiotherapy</arm_group_label>
    <other_name>5 FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Radiotherapy : 70Gy (2Gy/day) for 7 weeks.</description>
    <arm_group_label>Cisplatin and radiotherapy</arm_group_label>
    <arm_group_label>TPF followed by radiotherapy</arm_group_label>
    <other_name>radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Squamous cell carcinoma of the larynx or hypopharynx, histologically proven, locally&#xD;
             advanced:&#xD;
&#xD;
               -  T2 not accessible to a supra-cricoid partial laryngectomy or not,&#xD;
&#xD;
               -  T3 without massive infiltration by endolarynx transglottic injury,&#xD;
&#xD;
               -  N0 to N2c&#xD;
&#xD;
               -  No distant metastasis&#xD;
&#xD;
               -  No associated cancer or earlier&#xD;
&#xD;
          -  Patients Previously Untreated&#xD;
&#xD;
          -  Age&gt; 18 years and &lt;75 years&#xD;
&#xD;
          -  PS 0 or 1 according to WHO&#xD;
&#xD;
          -  Tumor volume assessable by RECIST.&#xD;
&#xD;
          -  Absence of distant metastasis, confirmed by chest TDM, abdominal ultrasound (or TDM)&#xD;
             in case of abnormal liver function and bone scan if local symptoms.&#xD;
&#xD;
          -  Absence of any participation in a clinical trial within 30 days prior to inclusion.&#xD;
&#xD;
          -  Absence of any concomitant cancer treatment.&#xD;
&#xD;
          -  Absence of any chronic treatment ( ≥3 months) with a daily corticosteroid dose is ≥20&#xD;
             mg / day of methylprednisolone or equivalent.&#xD;
&#xD;
          -  Hematological function: neutrophils ≥1.5 x 109 / L, platelets ≥100 x 109 / l,&#xD;
             hemoglobin ≥10 g / dl (or 6.2 mmol / l).&#xD;
&#xD;
          -  Hepatic function: normal total bilirubin; AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN (LNS)&#xD;
             of each center; alkaline phosphatase ≤ 5 x LNS.&#xD;
&#xD;
          -  Renal function: serum creatinine ≤ 120 mol / l (1.4 mg / dl); if creatinine &gt; 120 mol&#xD;
             / l, creatinine clearance should be ≥ 60 ml / min.&#xD;
&#xD;
          -  calculated creatinine clearance (Crockcroft formula) or measured ≥ 60 ml / min&#xD;
&#xD;
          -  Estimated life expectancy ≥ 3 months&#xD;
&#xD;
          -  Weight loss less than 10% over the last 3 months&#xD;
&#xD;
          -  VHI and DHI questionary&#xD;
&#xD;
          -  Quality of Life Questionnaire QLQ-C30 and QLQ-H &amp; N35&#xD;
&#xD;
          -  Patient has given its written consent before any specific procedure of the Protocol.&#xD;
&#xD;
          -  Women and men of childbearing age should have accepted a medically effective&#xD;
             contraception during the treatment period and at least 6 months after discontinuation&#xD;
             of study treatments (Docetaxel, 5-Fluorouracil and Cisplatin. If pregnancy is declared&#xD;
             by a patient or partner of a patient, it must be followed to know the evolution of&#xD;
             pregnancy.&#xD;
&#xD;
          -  Dynamic Vidéoscopie of deglutition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  transglottic T3 with massive infiltration of hemilarynx or T4 with massive&#xD;
             cartilaginous tumor lysis or reverse cricoarythénoïdenne region or posterior&#xD;
             hypopharyngeal wall&#xD;
&#xD;
          -  tumor requiring the completion of an immediately tracheotomy.&#xD;
&#xD;
          -  Tumour available immediately to partial surgery.&#xD;
&#xD;
          -  tumor requiring circular hypopharyngectomie&#xD;
&#xD;
          -  N3 nodal injury&#xD;
&#xD;
          -  Vaccination against yellow fever recent or anticipated&#xD;
&#xD;
          -  Deficit known dihydropyrimidine dehydrogenase (DPD)&#xD;
&#xD;
          -  Other malignancies within 5 years prior to randomization, with the exception of&#xD;
             adequately treated basal skin cancer and carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Patients with AST or ALT&gt; 1.5xULN associated with alkaline phosphatase &gt; 2.5x LNS will&#xD;
             not be eligible for testing.&#xD;
&#xD;
          -  symptomatic neuropathy grade ≥2 with NCI-CTC.&#xD;
&#xD;
          -  Clinical alteration of hearing function.&#xD;
&#xD;
          -  Other concomitant serious medical conditions (partial list):&#xD;
&#xD;
               -  Unstable cardiac disease despite treatment.&#xD;
&#xD;
               -  Myocardial infarction within 6 months prior to trial entry.&#xD;
&#xD;
               -  Neurological or psychiatric history such as dementia, seizures;&#xD;
&#xD;
               -  Severe uncontrolled infection.&#xD;
&#xD;
               -  Significant gastrointestinal abnormalities, including those that require&#xD;
                  parenteral nutrition, active peptic ulcer disease and a history of surgical&#xD;
                  procedures affecting absorption&#xD;
&#xD;
               -  Obstructive pulmonary disease requiring hospitalization in the year before&#xD;
                  inclusion.&#xD;
&#xD;
               -  Unstable diabetes or other cons-indications to corticosteroids.&#xD;
&#xD;
               -  Significant ophthalmologic abnormality.&#xD;
&#xD;
               -  Moderate or severe eczema.&#xD;
&#xD;
          -  Allergy to iodine.&#xD;
&#xD;
          -  Hypersensitivity to Docetaxel, Cisplatin or at one of their excipients.&#xD;
&#xD;
          -  Concomitant use of phenytoin, carbamazepine, barbiturates and rifampicin.&#xD;
&#xD;
          -  Presence, selection, psychological factors, family, social or geographical may alter&#xD;
             patient compliance with the study protocol and follow-up, a criterion of&#xD;
             non-inclusion. These factors should be discussed with the patient before inclusion in&#xD;
             the trial.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Patient (male or female) of childbearing age not taking adequate contraceptive&#xD;
             measures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles CALAIS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bretonneau, Service CORad Pôle Henry S Kaplan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles CALAIS, Pr</last_name>
    <phone>+ 33 247478265</phone>
    <email>gilles.calais@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Hélène GIRARD CALAIS</last_name>
    <phone>+33 247479121</phone>
    <email>rc.corad@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Bretonneau, Service CORad Pôle Henry S Kaplan</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles CALAIS, Pr</last_name>
      <phone>+ 33 247478265</phone>
      <email>gilles.calais@univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Hélène GIRARD CALAIS</last_name>
      <phone>+33 247479121</phone>
      <email>rc.corad@chu-tours.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Larynx, hypopharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

